dalteparin has been researched along with Asymptomatic Conditions in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Asymptomatic deep vein thrombosis (DVT) diagnosed with compression ultrasound (CUS) is a common endpoint in trials assessing the efficacy of anticoagulants to prevent venous thromboembolism (VTE), but the relationship of asymptomatic thrombus to mortality remains uncertain." | 2.87 | Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. ( Chi, G; Cohen, AT; Datta, S; Gibson, CM; Goldhaber, SZ; Gurin, M; Haroian, N; Harrington, RA; Hernandez, AF; Hull, RD; Kalayci, A; Korjian, S; Nafee, T; Qamar, I; Yee, MK, 2018) |
| " Adverse events, based on the Common Terminology Criteria for Adverse Events, Version 4, were recorded." | 1.42 | Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan. ( Eguchi, F; Goto, M; Miyamoto, S; Nakahara, H; Ogawa, M; Sanui, A; Satoh, S; Takashima, T; Tatsumura, M; Yoshizato, T, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nachega, JB | 1 |
| Ishoso, DK | 1 |
| Otokoye, JO | 1 |
| Hermans, MP | 1 |
| Machekano, RN | 1 |
| Sam-Agudu, NA | 1 |
| Bongo-Pasi Nswe, C | 1 |
| Mbala-Kingebeni, P | 1 |
| Madinga, JN | 1 |
| Mukendi, S | 1 |
| Kolié, MC | 1 |
| Nkwembe, EN | 1 |
| Mbuyi, GM | 1 |
| Nsio, JM | 1 |
| Mukeba Tshialala, D | 1 |
| Tshiasuma Pipo, M | 1 |
| Ahuka-Mundeke, S | 1 |
| Muyembe-Tamfum, JJ | 1 |
| Mofenson, L | 1 |
| Smith, G | 1 |
| Mills, EJ | 1 |
| Mellors, JW | 1 |
| Zumla, A | 1 |
| Mavungu Landu, DJ | 1 |
| Kayembe, JM | 1 |
| Kalayci, A | 1 |
| Gibson, CM | 1 |
| Chi, G | 1 |
| Yee, MK | 1 |
| Korjian, S | 1 |
| Datta, S | 1 |
| Nafee, T | 1 |
| Gurin, M | 1 |
| Haroian, N | 1 |
| Qamar, I | 1 |
| Hull, RD | 1 |
| Hernandez, AF | 1 |
| Cohen, AT | 1 |
| Harrington, RA | 1 |
| Goldhaber, SZ | 1 |
| Goto, M | 1 |
| Yoshizato, T | 1 |
| Tatsumura, M | 1 |
| Takashima, T | 1 |
| Ogawa, M | 1 |
| Nakahara, H | 1 |
| Satoh, S | 1 |
| Sanui, A | 1 |
| Eguchi, F | 1 |
| Miyamoto, S | 1 |
| Thachil, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| (Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218] | Phase 3 | 7,513 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.30 |
| Enoxaparin | 1.90 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.03 |
| Enoxaparin | 1.45 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.70 |
| Enoxaparin | 6.02 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.94 |
| Enoxaparin | 1.45 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.43 |
| Enoxaparin | 5.99 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 5.70 |
| Enoxaparin | 7.18 |
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.67 |
| Enoxaparin | 0.57 |
1 trial available for dalteparin and Asymptomatic Conditions
| Article | Year |
|---|---|
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asymptomatic Diseases; Benzamides; Enoxaparin; Female; Huma | 2018 |
3 other studies available for dalteparin and Asymptomatic Conditions
| Article | Year |
|---|---|
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatme | 2020 |
Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan.
Topics: Adult; Alanine Transaminase; Anticoagulants; Aspartate Aminotransferases; Asymptomatic Diseases; Bod | 2015 |
Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?
Topics: Adult; Anti-Bacterial Agents; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome | 2013 |